Top

Critical Care

Published in:

Open Access 01-12-2018 | Research

Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

Authors: A. Broeker, S. G. Wicha, C. Dorn, A. Kratzer, M. Schleibinger, F. Kees, A. Heininger, M. G. Kees, H. Häberle

Published in: Critical Care | Issue 1/2018

Abstract

Background

Tigecycline is a vital antibiotic treatment option for infections caused by multiresistant bacteria in the intensive care unit (ICU). Acute kidney injury (AKI) is a common complication in the ICU requiring continuous renal replacement therapy (CRRT), but pharmacokinetic data for tigecycline in patients receiving CRRT are lacking.

Methods

Eleven patients mainly with intra-abdominal infections receiving either continuous veno-venous hemodialysis (CVVHD, n = 8) or hemodiafiltration (CVVHDF, n = 3) were enrolled, and plasma as well as effluent samples were collected according to a rich sampling schedule. Total and free tigecycline was determined by ultrafiltration and high-performance liquid chromatography (HPLC)-UV. Population pharmacokinetic modeling using NONMEM® 7.4 was used to determine the pharmacokinetic parameters as well as the clearance of CVVHD and CVVHDF. Pharmacokinetic/pharmacodynamic target attainment analyses were performed to explore the potential need for dose adjustments of tigecycline in CRRT.

Results

A two-compartment population pharmacokinetic (PK) model was suitable to simultaneously describe the plasma PK and effluent measurements of tigecycline. Tigecycline dialysability was high, as indicated by the high mean saturation coefficients of 0.79 and 0.90 for CVVHD and CVVHDF, respectively, and in range of the concentration-dependent unbound fraction of tigecycline (45–94%). However, the contribution of CRRT to tigecycline clearance (CL) was only moderate (CL_CVVHD: 1.69 L/h, CL_CVVHDF: 2.71 L/h) in comparison with CL_body (physiological part of the total clearance) of 18.3 L/h. Bilirubin was identified as a covariate on CL_body in our collective, reducing the observed interindividual variability on CL_body from 58.6% to 43.6%. The probability of target attainment under CRRT for abdominal infections was ≥ 0.88 for minimal inhibitory concentration (MIC) values ≤ 0.5 mg/L and similar to patients without AKI.

Conclusions

Despite high dialysability, dialysis clearance displayed only a minor contribution to tigecycline elimination, being in the range of renal elimination in patients without AKI. No dose adjustment of tigecycline seems necessary in CRRT.

Trial registration

EudraCT, 2012–005617-39. Registered on 7 August 2013.

Available only for authorised users

Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7:1459–70.CrossRef

Morfin-Otero R, Dowzicky MJ. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the Tigecycline Evaluation and Surveillance Trial, 2004 to 2009. Clin Ther. 2012;34:101–12.CrossRef

Lewis SJ, Mueller BA. Antibiotic dosing in critically ill patients receiving CRRT: underdosing is overprevalent. Semin Dial. 2014;27:441–5.CrossRef

Eyler RF, Mueller BA. Antibiotic dosing in critically ill patients with acute kidney injury. Nat Rev Nephrol. 2011;7:226–35.CrossRef

Korth-Bradley JM, Troy SM, Matschke K, Muralidharan G, Fruncillo RJ, Speth JL, et al. Tigecycline pharmacokinetics in subjects with various degrees of renal function. J Clin Pharmacol. 2012;52:1379–87.CrossRef

Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid–base status. Crit Care Med. 2009;37:2018–24.CrossRef

Brandenburger T, Dimski T, Slowinski T, Kindgen-Milles D. Renal replacement therapy and anticoagulation. Best Pract Res Clin Anaesthesiol. 2017;31:387–401 Available from: https://doi.org/10.1016/j.bpa.2017.08.005.CrossRef

Dorn C, Kratzer A, Liebchen U, Schleibinger M, Murschhauser A, Schlossmann J, et al. Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration. J Pharm Sci. 2018;107:739–44. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022354917306299.CrossRef

Lindbom L, Pihlgren P, Jonsson EN, Jonsson N. PsN-Toolkit—a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed. 2005;79:241–57.CrossRef

10.

Anderson BJ, Holford NHG. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008;48:303–32 Available from: http://www.annualreviews.org/doi/10.1146/annurev.pharmtox.48.113006.094708.CrossRef

11.

Lee CS, Marbury TC, Benet LZ. Clearance calculations in hemodialysis: application to blood, plasma, and dialysate measurements for ethambutol. J Pharmacokinet Biopharm. 1980;8:69–81.CrossRef

12.

Li AMMY, Gomersall CD, Choi G, Tian Q, Joynt GM, Lipman J. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother. 2009;64:929–37 Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkp302.CrossRef

13.

Choi G, Gomersall CD, Tian Q, Joynt GM, Freebairn R, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med. 2009;37:2268–82 Available from: https://insights.ovid.com/crossref?an=00003246-200907000-00021.CrossRef

14.

Van Wart SA, Owen JS, Ludwig EA, Meagher AK, Korth-Bradley JM, Cirincione BB. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections. Antimicrob Agents Chemother. 2006;50:3701–7 Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.01636-05.CrossRef

15.

Van Wart SA, Cirincione BB, Ludwig EA, Meagher AK, Korth-Bradley JM, Owen JS. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol. 2007;47:727–37 Available from: http://doi.wiley.com/10.1177/0091270007300263.CrossRef

16.

Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52:204–10 Available from: http://aac.asm.org/cgi/doi/10.1128/AAC.00813-07.CrossRef

17.

Barbour A, Schmidt S, Ma B, Schiefelbein L, Rand KH, Burkhardt O, et al. Clinical pharmacokinetics and pharmacodynamics of tigecycline. Clin Pharmacokinet. 2009;48:575–84.CrossRef

18.

Veinstein A, Debouverie O, Gregoire N, Goudet V, Adier C, Robert R, et al. Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics. J Antimicrob Chemother. 2012;67:1047–8 Available from: https://academic.oup.com/jac/article-lookup/doi/10.1093/jac/dkr550.CrossRef

19.

Honore PM, Jacobs R, De Waele E, Van Gorp V, Spapen HD. The blind spot in high-dose tigecycline pharmacokinetics in critically ill patients: membrane adsorption during continuous extracorporeal treatment. Crit Care. 2015;19:24 Available from: http://ccforum.com/content/19/1/24.CrossRef

Title: Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study
Authors: A. Broeker
S. G. Wicha
C. Dorn
A. Kratzer
M. Schleibinger
F. Kees
A. Heininger
M. G. Kees
H. Häberle
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: Critical Care / Issue 1/2018
Electronic ISSN: 1364-8535
DOI: https://doi.org/10.1186/s13054-018-2278-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study

Abstract

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2018

Effect of plasma exchange in acute respiratory failure due to Anti-neutrophil cytoplasmic antibody-associated vasculitis

Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study

Before the ICU: does emergency room hyperoxia affect outcome?

Diaphragm dysfunction during weaning from mechanical ventilation: an underestimated phenomenon with clinical implications

Noise in the intensive care unit and its influence on sleep quality: a multicenter observational study in Dutch intensive care units

Value of variation index of inferior vena cava diameter in predicting fluid responsiveness in patients with circulatory shock receiving mechanical ventilation: a systematic review and meta-analysis